CD63 antigen Antibodies

CD63 antigen (CD63)

Plays a role in the activation of ITGB1 and integrin signaling, leading to the activation of AKT, FAK/PTK2 and MAP kinases. Promotes cell survival, reorganization of the actin cytoskeleton, cell adhesion, spreading and migration, via its role in the activation of AKT and FAK/PTK2.

Plays a role in VEGFA signaling via its role in regulating the internalization of KDR/VEGFR2. Plays a role in intracellular vesicular transport processes, and is necessary for normal trafficking of the PMEL luminal domain that is essential for the growth and maturation of melanocytes.

Gene Information

Human
Gene Name:	CD63
Uniprot:	P08962
Entrez:	967

Family

Belongs to:
tetraspanin (TM4SF) family

Alternative Names

CD63 antigen (melanoma 1 antigen); CD63 antigen; CD63 molecule; CD63; Granulophysin; Lamp-3; Lysosomal-associated membrane protein 3; ME491; melanoma 1 antigen; Melanoma-associated antigen ME491; melanoma-associated antigen MLA1; MLA1lysosome-associated membrane glycoprotein 3; Ocular melanoma-associated antigen; OMA81H; tetraspanin-30; Tspan30; tspan-30; TSPAN30granulophysin

Molecular Weight

Mass (kDA):
25.637 kDA

Genomic Context

Human
Location:	12q13.2
Sequence:	12; NC_000012.12 (55725323..55729673, complement)

Tissue Specificity

Detected in platelets (at protein level). Dysplastic nevi, radial growth phase primary melanomas, hematopoietic cells, tissue macrophages.

Subcellular Localizations

Cell membrane; Multi-pass membrane protein. Lysosome membrane; Multi-pass membrane protein. Late endosome membrane; Multi-pass membrane protein. Endosome, multivesicular body. Melanosome. Secreted, extracellular exosome. Cell surface. Also found in Weibel-Palade bodies of endothelial cells (PubMed:10793155). Located in platelet dense granules (PubMed:7682577). Detected in a subset of pre-melanosomes. Detected on intralumenal vesicles (ILVs) within multivesicular bodies (PubMed:21962903).

Diseases

• Allergy
• Tissue Adhesions
• Neoplasms
• Malignant Neoplasms
• Inflammation
• Anaphylaxis
• Melanoma
• Hiv Infections
• Neoplasm Metastasis
• Von Willebrand Disease
• Thrombosis
• Immunologic Deficiency Syndromes

• Carcinoma
• Hemorrhage
• Immediate Hypersensitivity
• Leukemia
• Urticaria
• Malignant Paraganglionic Neoplasm
• Cardiovascular Diseases

Interacting Proteins

• TIMP1

Pathways

• Platelet Activation
• Basophil Activation
• Secretion
• Localization
• Platelet Aggregation
• Transport
• Pathogenesis
• Cell Adhesion
• Sensitization
• Hypersensitivity
• Cell Activation
• Exocytosis
• Anaphylaxis

• Coagulation
• Endocytosis
• Immune Response
• Cell Proliferation
• Hemostasis
• Cell Migration
• Phagocytosis

PTMs

• Phosphorylation
• Glycosylation
• Cleavage
• Palmitoylation
• Dephosphorylation

• Ribosylation
• Ubiquitination
• Biotinylation
• Nitration
• Carboxylation

• Acetylation

Research Areas

• Autophagy
• Cytokine Research

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CD63

Best Uses Of The CD63 Marker

A ELISA kit is an excellent choice if you're looking to use the CD63 Marker in your research. A CD63 ELISA Kit has many advantages. The kit can be utilized in all kinds of experiments. It can also be customized to fit the needs of your research. This kit doesn't require minimum order quantities. It is applicable to researchers from all countries. For more details, visit Boster Bio's website.

The development of aptamers for CD63 protein

The identification of tumor-associated antibodies is possible using aptamers, which were designed with the CD63 protein. A variety of advantages of aptamers over antibodies have been mentioned in the design of aptamers. For instance, aptamers can be used to identify extracellular vesicles associated with tumors from cells in a mild environment. Aptamers also target small molecules, sugars, and lipids. Furthermore, aptamers can be enhanced by the use of artificial or modified nucleic acid, as well as counter-SELEX.

Extracellular vesicles, components found in mammalian fluids have been the focus of research as biomarkers for various kinds of diseases. By using next-generation sequencing techniques, RNA aptamers were identified. Two conserved motifs were used to determine the sequences. Most predicted a nonconserved loop structure or stem structure. CD spectroscopy confirmed the binding affinity of the Aptamers.

By using the anti-CD63 aptamer of ExoPCD's microfluidic chip Xu and colleagues. (145) were able to identify CD63 proteins on exosomes using a LOD of 4.39 x 3 particles/mL. The aptamer was also suited for the detection of exosomes using immobilization-free and label-free EC system.

DNA sequences with a primary amine group at the 3' end were purchased from Integrated DNA Technologies. They were dissolved in water to a concentration of 10 mM. They contained sequences corresponding to CD63, CD24, and EpCAM. The aptamer sequences were labeled with three fluorescent molecules and then added to a four-arm poly(ethylene glycol) with free amines.

The authors also attempted to shorten the full sequence of the CD63 protein. In addition, they chose sequences that contained nonconserved stem regions. These sequences had higher peaks in the respective rankings than the remaining candidate aptamers. In addition, these sequences had longer stems and were more stable. Thus, they were selected as representative aptamers. In this way, they could be used to target the CD63 protein.

The process of selecting high-affinity aptamers has been developed in three laboratories. The SELEX method, whose name stands for systematic evolution of ligands by experiential enrichment, is used. This method yields artificial nucleic acids called aptamers. They are useful for the identification of various clinically relevant biomarkers. Aptamers can detect different targets, including proteins, amino acids, and thin slices of tumors.

Cost of CD63 Marker

The CD63 Marker is used to monitor the activity and response of the disease. It is an invaluable diagnostic tool for the diagnosis of CSU. The cost of this test varies widely, depending on the laboratory used and the number of patients tested. The use of this marker can improve the management of CSU in patients who have been diagnosed with this disorder. The CD63 Marker is a noninvasive blood test that can be used to diagnose CSU in children.

It has been shown to interact with several proteins and cell processes. It has been found to interact with a protein known as tissue inhibitor of metalloproteinase-1. Originally, this protein inhibited cancer growth but later proved to have cancer-promoting properties. In addition, this protein is involved in the activation of basophil granulocytes. Several other diseases and disorders are associated with CD63, including hermansky-Pudlak syndrome and lysosomal storage pool deficiency.

The cost of CD63 Marker depends on the laboratory used to test your samples. The more expensive the test, the more expensive the procedure. The more accurate it is, the better your treatment. The test also provides you with a report on how well the cancer is progressing. For more information, visit the CD63 marker page on our website. Our goal is to help you find the best price for your CD63 Marker. When choosing a lab, always make sure you have all the information you need, including your test results.

One of the most important tests for CSU is CD63. It shows the greatest correlation between CD63 and basophil degranulation. In addition, CD63 expression on basophils correlates with ASST in autoimmune CSU, urticaria, and response to therapy in atopic diseases. The price of CD63 Marker depends on the lab's cost-of-analysis. The test can cost as little as $25.

Potential applications for aptamers in cancer therapeutics

A new screening method for aptamers has been developed to screen for the presence of molecular markers in cancer cells. This method uses a cell-SELEX screening platform, which is unique in its ability to generate a panel of aptamers while not requiring any prior knowledge of a cell's molecular signature. Cell-SELEX-screened aptamers have high affinity and specificity for cancer cells, which may enable broader applications of the technology in disease treatment. Current applications of cell-SELEX-screened aptamers include liver, lung, and brain cancers.

A new chemical antibody, called an aptamer, is being developed, which has several benefits over antibodies. The aptamer is smaller, more readily synthesized, and more easily manipulated than antibodies. This versatility and ease of synthesis has made it a potential target-designed cancer drug. Scientists have also designed new aptamer-drug conjugates, including phototherapy and chemotherapy.

Using DNA-silver nanoclusters, Yin et al. developed a label-free aptasensor that uses fluorescent DNA-silver nanoclusters as recognition probes. This aptamer is designed to recognize cancer cells by binding to the target's DNA. The aptamer's fluorescent property is changed in the presence of cancer cells, and the corresponding chemotherapeutic effect is carried out.

Despite being an excellent drug delivery system, many chemotherapeutic agents have toxicity and poor selectivity when applied to tumor cells. By using an aptamer-drug conjugate, researchers could directly target cancer cells with a single, small dose. They would also be able to avoid toxicity to healthy cells in the body, reducing the dose and enhancing therapeutic efficacy.

The aptamer-nanoparticle preparation method can extend the half-life of the drug in blood. Nanoparticles that have a high specific surface area and uniform morphology could improve drug delivery and distribution. In recent years, nanomaterials comprised of various materials, such as silica nanoparticles made of gold, silica, and aptamer-targeted drug models, have been developed.

A novel aptamer-nucleolin molecule called AS1411 was discovered by scientists in Korea and is currently being tested in clinical trials for leukemia. It inhibits the nuclear factor-kB function and destabilizes BCL-2's mRNA. In addition, aptamers exhibit high specificity for cancer and other tumors and are extremely resistant to different types of nuclease deficient medications.

Cost of ELISA test for CD63 Marker

The ELISA assay for CD63 markers is a simple and affordable method to determine the amount of human CD63 in serum, plasma, or tissue homogenates. The sensitivity and specificity of the CD63 assay are exceptional, and there isn't any significant cross-reactivity between human CD63 and any of its analogs. Biotin-antibody (1x) is added to the wells.

The ExoELISA Ultra CD63 kit significantly increases the sensitivity of detection of exosomes. It can also cut down the time of the assay by only four hours. The ExoELISA-ULTRA CD63 kit is compatible with almost all biofluids and comes with a calibrated internal standard for exosome detection. This kit includes all the necessary reagents, as well as the assay plate.

A commercial ELISA assay for CD63 Markers has multiple benefits. It can detect high levels of this protein in a variety of samples, from whole blood to human tissues. It also helps in screening patients for multiple cancers by identifying their cancer-related risk factors. Cost of ELISA assay for CD63 Marker increases when more than one sample is tested at the same time.